Equity Profile

NVS

Novartis AG

Health CarePharmaceuticals$292.6B

Jul21Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Novartis AG is a global healthcare company focused on pharmaceuticals. With a market cap of $293 billion, it plays a significant role in developing innovative medicines that address various health conditions, making it a key player in the healthcare sector.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a crucial indicator of the company's profitability and financial health.

$2.11

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NVS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+3.66%

Avg Stock Reaction

-1.57%

Last Quarter Recap

In Q1-2026, Novartis reported an EPS of $1.99, missing estimates by 5.60%. The stock reacted positively, gaining 0.91% the following day.

Management Promises & Guidance

Focus on pipeline development for new drugs.
Commitment to cost management and efficiency improvements.
Plans to enhance market access for existing products.

Expectations

Wall Street Expectations

Overall expectations are mixed as Novartis has a history of beating EPS estimates, but recent performance has shown volatility.

Bull Case

If Novartis can deliver strong EPS and show positive revenue growth, it could reaffirm investor confidence and drive the stock higher.

Bear Case

Conversely, if the company misses EPS estimates again or fails to provide clear guidance, it may lead to further declines in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$2.11

EPS is a crucial indicator of the company's profitability and financial health.

Revenue Growth

N/A

Revenue growth reflects the company's ability to expand its market presence and drive sales.

Market Reaction

N/A

Understanding how the stock typically reacts to earnings can provide insight into investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for Q2-2026?

EPS is a key measure of profitability and will heavily influence investor sentiment.

How is Novartis addressing challenges in its drug pipeline?

Investors will be keen to hear about the company's strategies for maintaining growth and innovation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly cautious about Novartis's growth potential, failing to recognize the strength of its drug pipeline and market position.

Supporting Evidence

Despite a recent EPS miss, Novartis has a strong history of recovering and exceeding expectations.

Options pricing suggests a larger move than historical averages, indicating potential for a surprise.

The company's commitment to innovation and market access could drive better-than-expected results.

Key Risk

If the EPS comes in above $2.11, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Novartis's ability to meet or exceed expectations, especially after recent mixed results.

Bull Confirmed If

An EPS of $2.11 or higher would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS below $1.99 would reinforce the bear case and raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±9.59%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move, indicating uncertainty around the earnings report.

Options are pricing ±9.6% while NVS has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

20.0%

Calls (11K)P/C Ratio: 1.10Puts (8K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Novartis beats expectations, history suggests the stock could rise by around 2.49% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

Should the company miss expectations, history suggests a potential decline of about 1.76%, raising concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug pipeline and any new product launches.
2Details on cost management strategies and operational efficiencies.
3Any commentary on market access improvements for existing products.
4Insights into competitive pressures and how Novartis plans to address them.
5Management's outlook for the remainder of the fiscal year.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

ICICI Bank Limited

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a crucial indicator of the company's profitability and financial health.

$2.11

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NVS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+3.66%

Avg Stock Reaction

-1.57%

Last Quarter Recap

In Q1-2026, Novartis reported an EPS of $1.99, missing estimates by 5.60%. The stock reacted positively, gaining 0.91% the following day.

Management Promises & Guidance

Focus on pipeline development for new drugs.
Commitment to cost management and efficiency improvements.
Plans to enhance market access for existing products.

Expectations

Wall Street Expectations

Overall expectations are mixed as Novartis has a history of beating EPS estimates, but recent performance has shown volatility.

Bull Case

If Novartis can deliver strong EPS and show positive revenue growth, it could reaffirm investor confidence and drive the stock higher.

Bear Case

Conversely, if the company misses EPS estimates again or fails to provide clear guidance, it may lead to further declines in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$2.11

EPS is a crucial indicator of the company's profitability and financial health.

Revenue Growth

N/A

Revenue growth reflects the company's ability to expand its market presence and drive sales.

Market Reaction

N/A

Understanding how the stock typically reacts to earnings can provide insight into investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported EPS for Q2-2026?

EPS is a key measure of profitability and will heavily influence investor sentiment.

How is Novartis addressing challenges in its drug pipeline?

Investors will be keen to hear about the company's strategies for maintaining growth and innovation.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly cautious about Novartis's growth potential, failing to recognize the strength of its drug pipeline and market position.

Supporting Evidence

Despite a recent EPS miss, Novartis has a strong history of recovering and exceeding expectations.

Options pricing suggests a larger move than historical averages, indicating potential for a surprise.

The company's commitment to innovation and market access could drive better-than-expected results.

Key Risk

If the EPS comes in above $2.11, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching Novartis's ability to meet or exceed expectations, especially after recent mixed results.

Bull Confirmed If

An EPS of $2.11 or higher would confirm the bull case and suggest strong operational performance.

Bear Confirmed If

An EPS below $1.99 would reinforce the bear case and raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±9.59%

Historical Avg

±2.5%

Pricing rich

The options market is pricing in a significant move, indicating uncertainty around the earnings report.

Options are pricing ±9.6% while NVS has averaged ±2.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

20.0%

Calls (11K)P/C Ratio: 1.10Puts (8K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Novartis beats expectations, history suggests the stock could rise by around 2.49% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

Should the company miss expectations, history suggests a potential decline of about 1.76%, raising concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug pipeline and any new product launches.
2Details on cost management strategies and operational efficiencies.
3Any commentary on market access improvements for existing products.
4Insights into competitive pressures and how Novartis plans to address them.
5Management's outlook for the remainder of the fiscal year.